CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

Table 4

Comparison of HE4, CA125, ROMA, and CPH-I among BOT I+II and EOC I+II group stratification by pathology.

	BOT I+II				EOC I+II
	Serous	Mucinous	Endometrioid	Clear cell	Serous	Mucinous	Endometrioid	Clear cell
HE4 (pmol/L)	49.8 (42.5-57.9)	45.3 (38.9-53.0)	57.4 (47.4-89.9)	37.8 (31.5-42.7)	130.6 (72.6-230.5)	57.3 (47.3-65.1)	91.9 (55.6-221.0)	64.8 (50.6-82.3)
CA125 (U/mL)	39.4 (19.6-86.5)	25.5 (17.9-37.2)	54.2 (24.8-127.3)	29.6 (22.7-53.5)	105.8 (55.5-392.9)	54.7 (16.0-117.8)	103.5 (32.1-251.8)	95.1 (34.5-180.3)
ROMA (%)	8.2 (5.5-12.5)	6.1 (4.2-9.6)	11.0 (7.0-43.8)	8.59 (3.0-18.4)	59.7 (23.5-81.9)	11.2 (7.1-14.0)^#	45.1 (10.6-82.0)	21.2 (9.4-32.0)
CPH-I (%)	1.8 (1.2-4.6)	1.0 (0.6-2.0)	1.9 (1.4-11.4)	1.5 (0.9-2.3)	30.4 (7.8-56.1)	3.0 (1.7-7.9)	11.4 (2.5-57.0)	7.3 (3.1-14.6)

Note: data are presented as the median (interquartile range). and ^# EOC I+II vs. BOT I+II in corresponding subgroups. Abbreviations: BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.